OPANA
LOE Approachingoxymorphone hydrochloride
NDAORALTABLET
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Clinical Trials (3)
COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients
Started Mar 2016
193 enrolled
HIV SeropositivityDyslipidemiasPCSK9
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
Started Nov 2007
50 enrolled
Pain
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
Started Nov 2007
32 enrolled
Pain